ReviewMicrobial biotechnology2025
Unlocking Enhanced Efficacy of Aminoglycoside Antibiotics Against Pseudomonas aeruginosa.
Review in Microbial biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- The Synergy Between a Silver-Ruthenium Antimicrobial and Aminoglycosides Is Based on Severe Macromolecular Damage.Molecular microbiology · 2026Article
- Gentamicin-Linked Supramolecular Hybrid Hydrogels: Mechanically Robust Cucurbit[7]Uril-Based Networks for Prolonged Infection Control.Advanced healthcare materials · 2026Article
- Implications of bacterial exposure to reactive oxygen and chlorine species.Infection and immunity · 2026Review
- The Synergy between a Silver-Ruthenium Antimicrobial and aminoglycosides is based on severe macromolecular damage.bioRxiv : the preprint server for biology · 2026Article
- Biological characterization and genome analysis of Pseudomonas phage ZAM-Pa99 as a promising anti-biofilm agent.Molecular biology reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Infectious diseases continue to be a global health burden. Among the major human pathogens is the Gram-negative bacterium Pseudomonas aeruginosa, which is particularly due to its wide range of drug resistance mechanisms. Aminoglycosides, which have long been used in treating pseudomonal infections, are increasingly undermined by resistance. This opinion article discusses the use and challenges of aminoglycosides against P. aeruginosa and highlights recent strategies that enhance aminoglycoside efficacy. These include combinational therapies, metabolic stimulants/adjuvants, silver, and more recently developed derivatives such as AGXX, many of which have been reported to potentiate the cytotoxic effects of aminoglycosides and re-sensitise aminoglycoside-resistant strains. While these findings pave the way for future therapies, the clinical relevance of many in vitro studies remains to be investigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.